Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AdAlta licenses Alzheimer's disease-specific shark antibodies to ...
AdAlta at a glance - AdAlta - next generation cell and protein therapeutics
Home - AdAlta - Developing i-body drugs to treat fibrotic diseases
Adalta Real - Bicester Vision
ADAlta (ASX: 1AD) - EmergingGrowth.com
Preference Test - AdAlta - next generation cell and protein therapeutics
AdAlta to support early return to clinical trials of AD-214 with rights ...
AdAlta investor briefing – progress of AD-214 Phase I extension study ...
AdAlta completes enrolment for AD-214 fibrosis safety trial - YouTube
AdAlta's i-body platform: reaching for the high-hanging fruit - AdAlta ...
AdAlta (ASX:1AD) showcased its clinical stage pipeline oppoertunities ...
AdAlta (ASX:1AD) has announced significant progress in Q4 FY24. Key ...
AdAlta presents at Investor Summit - AdAlta - next generation cell and ...
AD-214: A new approach to fibrotic disease - AdAlta - next generation ...
AdAlta proudly continues its series of posts on the specialists making ...
Break it Down: AdAlta moves into a higher realm of drug development ...
ADALTA EDUCATION SERIES, Issue One: Fibrosis - AdAlta - next generation ...
Home - AdAlta - next generation cell and protein therapeutics
Pulmonary Fibrosis Awareness Month 2017 - AdAlta - next generation cell ...
AdAlta (ASX:1AD) targeting idiopathic pulmonary fibrosis - Sequoia Direct
AdAlta completes enrolment for AD-214 fibrosis safety trial | ASX:1AD
AdAlta completes patient recruitment for AD-214 study to treat ...
ASX Health Stocks: AdAlta jumps 40pc after its fibrosis drug shows ...
#fibrosis #ipf #biotech | AdAlta Ltd
AdAlta links AD-214 results with efficacy thanks to new data - YouTube
AdAlta named as Finalist in Australian Technologies Competition ...
AdAlta locks in $3.7m to speed up Phase II clinical trials, near-term ...
ADALTA DEVELOPMENT LTD on LinkedIn: This is a powerful and intensive ...
Adalta logo - APR.Intern
AdAlta Rights Offer webinar recording, Wednesday 3 May 2023 - AdAlta ...
#1ad | AdAlta Ltd
Our October Highlights have landed for Adalta Global Inc.! What a month ...
AdAlta (Discovery Tools) 2026 Company Profile: Stock Performance ...
#1ad #webinar | AdAlta Ltd
AdAlta secures Cell Therapies as cellular immunotherapies manufacturer ...
AdAlta (ASX:1AD), in partnership with La Trobe University, AdAlta has ...
“East to West” product pipeline - AdAlta - next generation cell and ...
#1ad #biologics | AdAlta Ltd
Investor Factsheet - AdAlta - next generation cell and protein therapeutics
What’s in store for 2024: AdAlta | Stockhead
ADALTA DEVELOPMENT LTD on LinkedIn: Looking for a management and ...
AdAlta welcomes long-term support from Yuuwa Capital investors - YouTube
AdAlta Ltd on LinkedIn: "AdAlta is also delving into the popular ...
Adalta Global Inc. | LinkedIn
AdAlta partners with SYNthesis for immunotherapy launch | AdAlta Ltd ...
New peer reviewed publication for AdAlta Ltd's AD-214 out today | Tim ...
ADALTA DEVELOPMENT LTD on LinkedIn: This course offers the practical ...
topical - AdAlta - next generation cell and protein therapeutics
ASX:1AD - AdAlta presenting at 3rd ANZ Biologics Festival
StockTake: AdAlta eyes $1.3m boost to fuel East to West cellular ...
AdAlta (ASX:1AD) launches $1.2M placement to advance AD-214 clinical ...
AdAlta capitalises on $5-million raising to progress drug to treat ...
“East to West” strategy - AdAlta - next generation cell and protein ...
AdAlta Ltd's June 2025 Quarterly Report highlights tailwinds behind our ...
AdAlta Ltd on LinkedIn: #asx #biotech #fibrosis #ipf #adalta
AdAlta to present lead product AD-214 at MPGPCR 2023 pharmacology ...
AdAlta Ltd (ASX:1AD) has announced the acceleration of its “East to ...
AdAlta secures $1.9m from exercise of options to advance critical ...
AdAlta Ltd on LinkedIn: AdAlta Limited (ASX:1AD) will present at an ...
Adalta Engenharia - Crunchbase Company Profile & Funding
AdAlta (1AD): SYNThesis BioVentures MoU for Cellular Immunotherapies ...
AdAlta prioritises ‘East to West’ cellular immunotherapy strategy to ...
AdAlta on track to raise $3.15 million to fund early return to clinic ...
ADALTA DEVELOPMENT LTD on LinkedIn: Join us for our Equality and ...
ADALTA DEVELOPMENT LTD on LinkedIn: The primary goal of this course is ...
AdAlta delivers positive Phase I Extension Study results for AD-214 ...
ADALTA DEVELOPMENT LTD on LinkedIn: This award enables senior leaders ...
AdAlta Ltd on LinkedIn: #adalta #asx #fibrosis #biotech
#adalta #ad214 #1ad #fibrosis | AdAlta Ltd
Tips inför trädgårdssäsongen | AdAlta AB
AdAlta (ASX:1AD) - Webinar Presentation - YouTube
i-bodies - AdAlta - next generation cell and protein therapeutics
AdAlta (ASX:1AD) CEO, Tim Oldham, presented at the ChinaBio Partnering ...
AdAlta (ASX:1AD) - SYNthesis BioVentures partnership webinar recording ...
AdAlta gets commercial-ready after pre-clinical safety studies show ...
Navigate change confidently with the "Managing Change" course by Adalta ...
Bioshares: AdAlta prioritises IV formulation for AD-214 - AdAlta - next ...
AdAlta - 1AD(ASX) News & Expert Insights from Stockhead
AdAlta talks i-body technology ahead of Peak Asset Management ...
AdAlta secures A$1.28 million in rights offer to advance AD-214 - YouTube
ADALTA, expert-comptable à Perpignan et en Cerdagne
"AdAlta has ranked its East to West cellular immunotherapy strategy as ...
Road to 2025: AdAlta's push to advance lead drug AD-214 for deadly IPF ...
Unlocking Chronic Diseases with Next-Gen i-body Platform Technology ...
Long Shortz with AdAlta: Growing in confidence every day for fibrotic ...
AdAlta: A big development for fibrosis sufferers … and it could be ...
AdAlta’s Ad-214 extension study reaches milestone for Phase II clinical ...
Training Provider of the Year Winners - CMI
WTF with 1AD: New approach to treating fibrosis with lead i-body drug ...
‘World first’: AdAlta’s i-body platform a breakthrough for malaria ...
The creation and commercialisation of drug candidates originating from ...
AdAlta, SYNthesis collaborate on cell-based cancer immunotherapy | NT News
Catalogo Generale catalogo completo su: www.adalta.it
#adalta #ad214 #fibroticdiseases #biotechnology #cellularimmunotherapy ...
Being able to simulate different dose intervals, levels and routes of ...
Channel Partner Listing | Bentley Systems
AdAlta（ASX:1AD）单周暴涨翻番：与上海细胞治疗集团签署开发协议 “东向西”战略启动 加速中国CAR-T疗法走向全球 - 澳洲财经 ...
AdAlta, Industry and Community, La Trobe Industry, Case studies, La ...
ENPICOM: Unified bioinformatics for AI and lab scientists
These qualifications are designed for practising middle managers and ...
This Emotional Intelligence course is designed to help managers and ...
